Patient-reported outcomes

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov, Merrick Ross

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 72; DOI: 10.1186/s40425-017-0276-8
The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31^st Anniversary Annual Meeting
Howard L. Kaufman, Michael B. Atkins, Adam P. Dicker, Heather S. Jim, Louis P. Garrison, Roy S. Herbst, William T. McGivney, Steven Silverstein, Jon M. Wigginton, Peter P. Yu

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 38; DOI: 10.1186/s40425-017-0241-6

Main menu